Genome Editing– tag –
-
Scribe Therapeutics Achieves $129M IPO, Targeting Cardiometabolic Diseases with Reversible Epigenetic Gene Silencing
BioPharma Dive USA Overview Scribe Therapeutics successfully completed a $129 million IPO, marking the first gene editing company to go public in over two years. The company develops an epigenetic approach that silences gene expression w... -
Global Pluripotent Stem Cell Therapies Progress to 115 Clinical Trials with Over 1,200 Patients, Demonstrating Strong Safety Profile
Vertex AI Search Global Overview Global clinical trials involving pluripotent stem cell therapies have significantly advanced, with 115 trials treating over 1,200 patients by December 2024, reporting no major safety concerns. This progre... -
CRISPR Gene Editing Therapy Trials Surge to Over 100 Globally, Demonstrating High Precision and Efficacy for Genetic Disorders like Sickle Cell Disease
SciHive USA Overview As of 2026, clinical trials for CRISPR gene-editing therapies have surged to over 100 globally, attracting significant anticipation for their potential to treat various diseases. A recent report by NVIDIA highlights ... -
Beyond RNA: DNA-Guided CRISPR Heralds a New Era of Precision Gene Editing
Liv Hospital Turkey Overview Liv Hospital reports a significant shift in CRISPR gene editing, moving from conventional RNA-guided to potentially more stable and precise DNA-guided systems. This evolution, coupled with advancements in del... -
NIH-Funded Team Discovers Miniaturized CRISPR Enzyme Al3Cas12f, Enabling Precision In Vivo Gene Delivery via AAV Vectors
National Institutes of Health (NIH) USA Overview An NIH-funded research team has discovered a novel, enhanced miniaturized CRISPR gene-editing system, a natural enzyme named 'Al3Cas12f,' capable of targeted in vivo delivery. This enzyme ... -
Gene and Cell Therapy See Multiple Breakthroughs: Orca Bio’s TREGZI Receives FDA Approval, Vertex/CRISPR’s CASGEVY Expands Pediatric Indication, and Carsgen’s Satri-cel Gains China Approval
YouTube (LucidQuest) USA, China Overview According to a July 9, 2026, gene and cell therapy update, Orca Bio's precision engineered cell therapy, TREGZI, received FDA approval, offering a new option for matched donor allogeneic transplan... -
U.S. FDA RMAT Designations Surge to 165 Total, with Rocket Pharmaceuticals (5) and CRISPR Therapeutics (4) Leading the Way
BioInformant USA Overview As of July 15, 2026, the cumulative number of Regenerative Medicine Advanced Therapy (RMAT) designations publicly announced by the U.S. FDA has reached 165. Rocket Pharmaceuticals and CRISPR Therapeutics are not... -
REPROCELL Unveils StemEdit Hypoimmune iPSCs with HLA Knockout, Accelerating Development of Off-the-Shelf Cell Therapies
REPROCELL (Blog) Japan Overview REPROCELL has announced the launch of its StemEdit hypoimmune iPSC lines, featuring HLA knockout through high-efficiency genome editing and regulatory-compliant cell lines. This technology aims to mitigate... -
Scribe Therapeutics Files for Nasdaq IPO, Advancing CRISPR-Based Cardiovascular Disease Platform STX-1150 for Hypercholesterolemia
Endpoints News USA Overview Scribe Therapeutics, co-founded by Nobel laureate Dr. Jennifer Doudna, has filed for an initial public offering (IPO) on Nasdaq. This move signals a crucial strategy for the company to expand its CRISPR-based ... -
FDA Approves Casgevy for Expanded Use in Pediatric Patients Aged 2 and Older with Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Seeking Alpha USA Overview Crispr Therapeutics and Vertex Pharmaceuticals announced that the U.S. FDA has approved an expanded indication for Casgevy (exagamglogene autotemcel) to include pediatric patients aged 2 and older with sickle c...
